Analyst Research

Report Title Price
Provider: S&P Capital IQ Quantitative Report
$127.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

OPKO Health Inc Completes Acquisition of Cytochroma Inc


Monday, 4 Mar 2013 04:27pm EST 

OPKO Health Inc announced that it has completed the acquisition of Cytochroma Inc. (Markham, Canada). Cytochroma`s lead products include CTAP101 Capsules, a vitamin D prohormone to treat secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency, and Fermagate Tablets, a new and potent non-absorbed phosphate binder to treat hyperphosphatemia in CKD patients on chronic hemodialysis. 

Latest Key Developments in Pharmaceuticals

Company Quote

8.99
0.22 +2.51%
11 Jul 2014